ORLANDO, FL, USA (UroToday.com) - Gwenaelle Gravis, MD, from Institut Paoli-Calmettes in France presented long-term analysis of GETUG-AFU 15 which tested ADT vs ADT + docetaxel in 385 hormone naïve metastatic prostate cancer patients on intent-to-treat basis.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients received LHRH or maximum androgen blockade in addition to docetaxel 75 mg/m2 IV every 3 weeks (up to 9 cycles). Although there was a 14-month overall survival advantage in the combination therapy group, this did not reach statistical difference after 83 months median follow up (the initial report had 50 month median follow up). A subcohort analysis stratifying high- versus low-volume disease after ADT or ADT+ docetaxel also revealed no statistical difference in overall survival. However, Eric Small, MD, from UCSF gave a thorough post-mortem examination of the trial and pointed out several caveats to those interpreting the trial as negative. He compared the GETUG-AFU 15 trial to the CHAARTED trial presented by Dr. Christopher Sweeney at the ASCO 2014 meeting comparing the same two treatments in hormone naïve patients and which showed a significant overall survival advantage. In GETUG-AFU 15 there were less high-volume metastases patients. In CHAARTED, the effect was most pronounced in patients with high-0volume disease. There was also a much higher amount of post protocol docetaxel in the ADT-only group compared to CHAARTED which may have clouded the long-term results.
Lastly, in CHAARTED, post protocol abirarterone or enzalutamide was fairly equal in both groups but this is unknown in GETUG-AFU 15. Dr. Small concluded that upfront docetaxel is beneficial in hormone-naïve metastatic prostate cancer based on the results of CHAARTED and the design and post-protocol treatments which confound interpretation of GETUG- AFU15.
Presented by Gwenaelle Gravis, MD at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Institut Paoli-Calmettesm, Marseille, France
Reported by Phillip Abbosh, MD, PhD medical writer for UroToday.com